Treatment of recent-onset type 1 diabetic patients with DiaPep277: results of a double-blind, placebo-controlled, randomized phase 3 trial.

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F14%3A33149272" target="_blank" >RIV/61989592:15110/14:33149272 - isvavai.cz</a>

Result on the web

<a href="http://care.diabetesjournals.org/content/37/5/1392.long" target="_blank" >http://care.diabetesjournals.org/content/37/5/1392.long</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.2337/dc13-1391" target="_blank" >10.2337/dc13-1391</a>

Result language

angličtina

Original language name

Treatment of recent-onset type 1 diabetic patients with DiaPep277: results of a double-blind, placebo-controlled, randomized phase 3 trial.

Original language description

OBJECTIVE: To evaluate safety and efficacy of DiaPep277 in preserving beta-cell function in type 1 diabetic patients.RESEARCH DESIGN AND METHODS: DIA-AID 1 is a multinational, phase 3, balanced-randomized, double-blind, placebo-controlled, parallel-groupclinical study. Newly diagnosed patients (N = 457, aged 16-45 years) were randomized to subcutaneous injections of DiaPep277 or placebo quarterly for 2 years. The primary efficacy end point was the change from baseline in the area under the glucagon-stimulated C-peptide curve. Secondary end points were the change from baseline in mixed-meal stimulated C-peptide secretion and in fasting C-peptide and achieving target HbA1c ?7% (?53 mmol/mol). Partial remission (target HbA1c on insulin ?0.5 units/kg/day)and hypoglycemic event rate were exploratory end points.RESULTS: DiaPep277 was safe and well tolerated. Significant preservation of C-peptide secretion was observed in the DiaPep277-treated group compared with the placebo (relative treat

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FB - Endocrinology, diabetology, metabolism, nutrition

OECD FORD branch

—

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2014

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Diabetes Care

ISSN

0149-5992

e-ISSN

—

Volume of the periodical

37

Issue of the periodical within the volume

5

Country of publishing house

US - UNITED STATES

Number of pages

9

Pages from-to

1392-1400

UT code for WoS article

—

EID of the result in the Scopus database

—